All In Biotech

BLA 103293 · Chiron

Proleukin

Aldesleukin · Lymphocyte Growth Factor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Sep 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

May 5, 1992

Approved uses

3

Original approval plus efficacy supplements

Registered trials

528

39 Phase 3, 38 recruiting

FAERS reports

1,262

1,172 serious, 211 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CAPILLARY LEAK SYNDROME (CLS), NEUROLOGIC TOXICITIES and SERIOUS INFECTIONS Capillary leak syndrome (CLS), including life threatening or fatal reactions, has occurred in patients treated with Proleukin. Do not administer Proleukin to patients with significant cardiac, pulmonary, renal, and hepatic impairment. Administer Proleukin in a hospital setting with an intensive care facility. Withhold or discontinue Proleukin as recommended [see Dosage and Administration (2.4) , Contraindications (4) , Warnings and Precautions (5.1) ] . Neurologic toxicities, which may be life-threatening or result in coma or permanent neurological deficits, have occurred in patients treated with Proleukin. Withhold or discontinue Proleukin as recommended [see Dosage and Administration (2.4) , Warnings and Precautions (5.2) ] . Serious Infections including sepsis and bacterial endocarditis have occurred...

What it is approved for

From the label in effect Dec 20, 2024.

Proleukin is a lymphocyte growth factor indicated for: The treatment of adults with metastatic renal cell carcinoma. ( 1.1 ) The treatment of adults with metastatic melanoma. ( 1.2 ) 1.1 Metastatic Renal Cell Carcinoma Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC). 1.2 Metastatic Melanoma Proleukin is indicated for the treatment of adults with metastatic melanoma.

Mechanism: Aldesleukin is an interleukin-2 lymphocyte growth factor. The antitumor activity of aldesleukin has not been fully characterized. In vitro studies performed on human cell lines show enhancement of lymphocyte mitogenesis and cytotoxicity, induction of killer cell activity [lymphokine-activated killer (LAK) and natural killer (NK) cells] and interferon gamma production, and proliferation of human interleukin-2-dependent cell lines. Administration of aldesleukin in animals and humans produces multiple immunological effects in a dose-dependent manner. These effects include activation of cellular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 9, 1998 Supplement 1019 · Efficacy
  • Jan 9, 1998 Supplement 1021 · Efficacy · priority review ReviewLetter
  • May 5, 1992 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • PROLEUKIN · ALDESLEUKIN 22MIU/VIAL · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aldesleukin" as an intervention, any sponsor and status, largest first.

All 528 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia153
  • hypotension112
  • off label use107
  • thrombocytopenia84
  • diarrhoea82
  • vomiting71
  • nausea69
  • fatigue67
  • chills65
  • dyspnoea65
  • febrile neutropenia64
  • pain62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200492
2005103
200648
200754
200855
200941
201042
201149
201235
201328
201412
201520
201624
201751
201812
201941
202068
202172
202244
202356
2024111
2025130
202674

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Chiron

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.